OrbitonOpen research workspace →
Atyr Pharma Inc. logo

Atyr Pharma Inc.

NASDAQ:ATYRLive AI agent

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.

Investor website: https://atyrpharma.com/

About

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Their lead therapeutic candidate, efzofitimod, is in clinical development for interstitial lung disease (ILD), targeting immune-mediated disorders that cause chronic inflammation and fibrosis of the lungs. The company is focused on unlocking therapeutic intervention points through its proprietary library of tRNA synthetase-derived domains.

Verified company data

Cash position
$0.34
Shares outstanding
98,087,425
Projects
["Efzofitimod <br>NRP2 modulator | Pulmonary Sarcoidosis(1) | Phase 3","SSc-ILD | Phase 2","Other ILD (CTD-ILD; CHP) | Phase 1","ATYR0101 <br>LTBP1 modulator | Fibrosis | Preclinical","ATYR0750 <br>FGFR4 modulator | Liver Disorders | Preclinical","tRNA Synthetase Candidates(2) | | Preclinical"]
Leadership
Sanjay S. Shukla, M.D., M.S. (President and CEO, Director), Jill M. Broadfoot (Chief Financial Officer), Nancy E. Denyes (General Counsel), Leslie Nangle, Ph.D. (VP, Research), Danielle Campbell (VP, Human Resources), Lisa Carey (VP, Clinical Operations), Darin Lee, Ph.D. (VP, Technical Operations), Brandon Yaras (Vice President, Finance), Timothy P. Coughlin (Chairman), Jane A. Gross, Ph.D. (Director), Svetlana Lucas, Ph.D. (Director), Sanjay S. Shukla, M.D., M.S. (Director), Sara L. Zaknoen, M.D. (Director), Eric Benevich (Director)

Verified data last updated:

Recent filings